Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 216 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 DIY Mosquito Traps & Deterrents (That Really Work) June 23, 2021 No Link Between Caffeine Consumption and Breast Cancer, Study Finds September 29, 2021 Load more HOT NEWS A New Era of Early Cancer Detection With Blood Test May... How you can do your part in the AI transformation of... Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer
